Generation Bio Co. (GBIO)
NASDAQ: GBIO · Real-Time Price · USD
6.66
+0.05 (0.76%)
At close: Aug 14, 2025, 4:00 PM
6.37
-0.29 (-4.35%)
After-hours: Aug 14, 2025, 5:21 PM EDT
Company Description
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.
It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity.
The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Cameron McDonough |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 655 7500 |
| Website | generationbio.com |
Stock Details
| Ticker Symbol | GBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001733294 |
| CUSIP Number | 37148K209 |
| ISIN Number | US37148K2096 |
| Employer ID | 81-4301281 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Geoffrey McDonough M.D. | President, Chief Executive Officer and Director |
| Antoinette Paone M.B.A., M.S. | Chief Operating Officer |
| Dr. Phillip Samayoa Ph.D. | Chief Scientific Officer |
| Dr. Mark D. Angelino Ph.D. | Co-Founder |
| Dr. Robert Kotin Ph.D. | Co-Founder |
| Kevin John Conway | Chief Financial Officer |
| Yalonda Howze J.D. | Chief Legal Officer and Secretary |
| Jasmin Tower | Chief Human Resources Officer |
| Caitlin Cooper M.B.A. | Senior Vice President and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 17, 2025 | SCHEDULE 13G/A | Filing |
| Jun 5, 2025 | 8-K | Current Report |
| May 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |